Tiziana Life Sciences Ltd. (TLSA)
Tiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injury
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced positive results from studies of a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). SCI represents a major global health concern with significant effects on mortality and long-term disability, the company said in a statement on Thursday.
Tiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with its novel therapy nasal foralumab. The company's study detected changes in gene expression starting three months after patients received intranasal foralumab in the ongoing ISPPEA (Expanded Access Program).
Tiziana Life Sciences welcomes publication of article highlighting foralumab's potential in neurological diseases
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a review article in Nature Reviews Neurology that examines the potential of its lead therapeutic candidate intranasal foralumab in treating various neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's disease, ALS, and Parkinson's disease. The article, titled “Immune mechanisms and shared immune targets in neurodegenerative diseases,” emphasizes the immune system's role as a primary driver in diseases like MS or an amplifying factor in conditions such as Alzheimer's, ALS, and Parkinson's.
Tiziana Life Sciences doses first Alzheimer's patient with intranasal foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company said this milestone took place at Brigham and Women's Hospital in Boston as part of a study aimed at addressing neuroinflammation, a key factor in Alzheimer's progression.
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to additional trial sites across the Northeast of the United States. The trial sites include highly-regarded institutions, including Yale University, Johns Hopkins University, Cornell University, University of Buffalo, University of Massachusetts, and Thomas Jefferson University.
Tiziana Life Sciences secures grant for ALS trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Program which will be used for a 20-patient study investigating the safety and early efficacy of its investigational drug intranasal foralumab in patients with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.
Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI
Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings.
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured up to $10 million in funding through a registered direct offering. The offering includes an initial investment of approximately $5 million raised through the sale of 5,263,158 common shares at $0.95 each, with closing expected around November 1, 2024, The agreement also includes an option allowing the investor to acquire an additional 5,263,158 shares at the same price within 75 days, potentially bringing in another $5 million.
Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer's disease. The company has been developing a fully human, anti-CD3 monoclonal antibody called intranasal foramulab, which has demonstrated a favorable safety profile and clinical response in studies to date.
Tiziana Life Sciences names new chief executive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the appointment of Ivor Elrifi as its CEO, replacing acting CEO Gabriele Cerrone who will remain in his role as executive chairman of the board. The company highlighted that Elfiri previously served as the global head of the Patent Group at Cooley since 2014, and before that, he led the Patents division at Mintz Levin from 1999 to 2014.
Tiziana Life Sciences secures $3.4M in non-dilutive funding
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that foralumab is the only fully human anti-CD3 monoclonal antibody (mAb), which binds to the T cell receptor and dampens inflammation by modulating T cell function, therefore suppressing effector features in multiple immune cell subsets.
Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's disease with its investigational therapeutic intranasal foralumab. Expanded access INDs allow patients to gain access to investigational drugs, biologics and medical devices to treat serious diseases and conditions for which there are no comparable or satisfactory therapy options outside of clinical trials, the biopharmaceutical company said.
